Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health's Breast Cancer Test Listed in NCCN's Guidelines

NEW YORK (GenomeWeb News) - Genomic Health said today that its predictive breast cancer assay has been included in the National Comprehensive Cancer Network’s 2008 Breast Cancer Treatment Guidelines.
 
The company’s Oncotype DX is a multi-gene expression test used to predict the chances of breast cancer recurrence and the likelihood that chemotherapy will benefit certain patients, the company said.
 
NCCN is an alliance of 21 cancer centers aimed at improving care and treatments for cancer patients.
 
In October, the American Society of Clinical Oncology recommended using Oncotype DX in its updated guidelines for using breast cancer tumor markers.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.